Compare BIO-TECHNE Corp (TECH) vs Zoom Video Communications, Inc. (ZM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BIO-TECHNE Corp vs Zoom Video Communications, Inc. — how do they compare? BIO-TECHNE Corp trades at $72.13 (market cap $11.24B), while Zoom Video Communications, Inc. trades at $105.77 (market cap $31.43B). The key difference: Zoom Video Communications, Inc. is far larger — about 2.8× BIO-TECHNE Corp's market cap, and BIO-TECHNE Corp pays a 0.44% dividend while Zoom Video Communications, Inc. pays none. Which is the better fit depends on your goals.
| TECH | ZM | |
|---|---|---|
Market Cap | $11.24B | $31.43B |
Sector | Health | Technology |
52-Week High | $72.29 | $111.88 |
52-Week Low | $43.31 | $69.77 |
Enterprise Value | $11.32B | $23.77B |
Dividend Yield | 0.44% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bio-Techne (TECH) trades at $72.29, up 0.54% today, with a bullish technical signal from moving averages and a consensus analyst price target of $71.67. Recent earnings showed mixed results, with a Q4 2025 beat but a Q1 2026 miss. The company maintains strong gross margins at 64.96% but faces declining net income margins, down to 6.01% in 2025. Positive cash flow trends and a pending acquisition by Merck highlight ongoing corporate developments.
Outlook is balanced with growth potential from product innovation and acquisition synergies, but risks include earnings volatility, high valuation multiples, and shareholder litigation over the merger terms. Institutional sentiment is split evenly between buy and hold ratings, reflecting cautious optimism amid execution challenges.
Zoom Communications (ZM) trades at $104.50, up 3.16% on the day, with a bullish technical signal and strong moving average support. The stock shows robust profitability with a 77.4% gross margin and 42% net income margin, while recent earnings beat expectations in Q1 2026. Analyst consensus price target is $118.79, suggesting potential upside from current levels. Recent news highlights insider selling and AI product developments, including Zoom Virtual Agent Receptionist launches and APAC leadership appointments.
Outlook remains cautiously optimistic with solid fundamentals and technical momentum, but risks include insider selling pressure and competitive threats. The stock's valuation at 15.4x P/E appears reasonable given earnings growth, though investors should monitor Q2 2026 earnings due August 25, 2026, for confirmation of sustained performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →About Zoom Video Communications, Inc.
Zoom Video Communications, Inc. develops a people-centric cloud service that transforms real-time collaboration experience. The Company offers unified meeting experience, a cloud service that provides a 3-in-1 meeting platform with HD video conferencing, mobility, and web meetings. Zoom Video Communications serves customers worldwide.
Read more on ZM →
